Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 715 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis, Pulmonary Clear all
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 2, 2026, 5:56 AM EDT
Completed No phase listed Observational

Patient Outcomes of Clinic Transition From Face to Face Encounter to Telemedicine in Cystic Fibrosis

NCT04402801
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years
Enrollment
140 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Not applicable Interventional

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Pilot Study

NCT04608019
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Immediate Antibiotics, Tailored Treatment
Other
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
6 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 2, 2026, 5:56 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor

NCT03367494
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Measurement of Sweat Chloride and Sweat Bromide
Diagnostic Test
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 2, 2026, 5:56 AM EDT
Withdrawn Not applicable Interventional

The Relationship Between CFTR Gene Mutations and Exercise Capacity

NCT05157646
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Fitness tracker
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

NCT01404234
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 12 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

NCT03224351
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

NCT07349394
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA, Rosuvastatin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 2, 2026, 5:56 AM EDT
Completed No phase listed Observational Results available

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

NCT04378153
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
80
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 2, 2026, 5:56 AM EDT
Recruiting Not applicable Interventional

Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials

NCT04580368
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
CFTR Modulators
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function

NCT01494909
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ensure plus
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
10 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MRI for Non-Invasive Imaging in Neonates and Children

NCT02163681
View directory record Official record
Conditions
Healthy, Cystic Fibrosis (CF), Asthma, Bronchopulmonary Dysplasia (BPD)
Interventions
Hyperpolarized Helium-3 MRI of the chest
Drug
Lead sponsor
University of Virginia
Other
Eligibility
4 Months to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 3 Interventional

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

NCT00432861
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
PANCRECARB® (pancrelipase), Placebo
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
7 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 1 Interventional Results available

Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis

NCT01094704
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
sodium chloride (7%)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Not applicable Interventional

Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo

NCT02661438
View directory record Official record
Conditions
Bronchiectasis, Pulmonary Disease, Chronic Obstructive
Interventions
Placebo to Ciprofloxacin DPI (BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Vero Beach, Florida • Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 2, 2026, 5:56 AM EDT
Completed No phase listed Observational

Molecular Phenotypes for Cystic Fibrosis Lung Disease

NCT01116414
View directory record Official record
Conditions
Cystic Fibrosis, Lung Diseases
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

NCT02392234
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661/Ivacaftor, Ivacaftor, Placebo matched to VX-661/ ivacaftor, Placebo matched to Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)

NCT02139306
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren (PTC124®), Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Birmingham, Alabama • Mobile, Alabama • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 2, 2026, 5:56 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

NCT02498535
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nitric Oxide 160 ppm
Drug
Lead sponsor
Novoteris, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Garden Grove, California • Los Angeles, California • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Redox Imbalance and the Development of Cystic Fibrosis Diabetes

NCT02202876
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cystic Fibrosis
Interventions
Oral Glucose Tolerance Test, High Glycemic Index Meal, Low Glycemic Index Meal, Test Soda, Fruit juice
Other
Lead sponsor
Emory University
Other
Eligibility
1 Year and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 2, 2026, 5:56 AM EDT
Withdrawn Not applicable Interventional

Metabolic Abnormalities in Hispanic Children With Cystic Fibrosis

NCT00287443
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Oral Glucose tolerance test, Whole body protein turnover, IV glucose tolerance test, Indirect Calorimetry, Dual Energy X-ray Absorptiometry (DEXA), Growth Hormone Stimulation Test
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis

NCT01859390
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AquADEKs-2, control multivitamin
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Aurora, Colorado • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Not applicable Interventional Results available

Ketone Supplementation in Cystic Fibrosis

NCT04938726
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ketone Monoester
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 2, 2026, 5:56 AM EDT
Completed Phase 1 Interventional

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

NCT00308243
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sodium Pyruvate in 0.9% Sodium Chloride Solution
Drug
Lead sponsor
Emphycorp
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Oct 2, 2026, 5:56 AM EDT